Rep. Lisa C. McClain Sells Off Shares of Pfizer Inc. (NYSE:PFE)

Representative Lisa C. McClain (R-Michigan) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on September 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Pfizer stock on August 4th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $50,001 – $100,000 in shares of Taiwan Semiconductor Manufacturing (NYSE:TSM) on 8/28/2025.
• Purchased $1,001 – $15,000 in shares of ACI Worldwide (NASDAQ:ACIW) on 8/19/2025.
• Purchased $1,001 – $15,000 in shares of HCA Healthcare (NYSE:HCA) on 8/19/2025.
• Sold $1,001 – $15,000 in shares of Amedisys (NASDAQ:AMED) on 8/18/2025.
• Purchased $1,001 – $15,000 in shares of Kite Realty Group Trust (NYSE:KRG) on 8/13/2025.
• Sold $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 8/13/2025.
• Purchased $1,001 – $15,000 in shares of JD.com (NASDAQ:JD) on 8/13/2025.
• Sold $1,001 – $15,000 in shares of Trade Desk (NASDAQ:TTD) on 8/13/2025.
• Sold $1,001 – $15,000 in shares of US Foods (NYSE:USFD) on 8/13/2025.
• Purchased $1,001 – $15,000 in shares of Agree Realty (NYSE:ADC) on 8/13/2025.

Pfizer Price Performance

Pfizer stock opened at $24.03 on Monday. The firm has a 50-day moving average price of $24.63 and a 200-day moving average price of $24.20. The firm has a market capitalization of $136.62 billion, a PE ratio of 12.78, a price-to-earnings-growth ratio of 0.78 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the business earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is 91.49%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Bank of America lifted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Berenberg Bank decreased their price objective on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a report on Thursday, May 29th. Citigroup lifted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Morgan Stanley lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Finally, Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $28.12.

Hedge Funds Weigh In On Pfizer

Several large investors have recently made changes to their positions in PFE. Capital Advisory Group Advisory Services LLC raised its holdings in Pfizer by 2.9% during the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock valued at $328,000 after acquiring an additional 388 shares during the period. Citizens National Bank Trust Department raised its holdings in Pfizer by 0.9% during the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock valued at $1,118,000 after acquiring an additional 395 shares during the period. Peak Asset Management LLC raised its holdings in Pfizer by 1.4% during the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after acquiring an additional 402 shares during the period. Able Wealth Management LLC raised its holdings in Pfizer by 2.0% during the 2nd quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock valued at $512,000 after acquiring an additional 413 shares during the period. Finally, Trust Co of the South increased its holdings in shares of Pfizer by 1.5% in the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock worth $712,000 after purchasing an additional 441 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.